Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StoP CDI: Vancomycin Prophylaxis for C. difficile
NCT02996487Phase 4Completed
- Sponsor
- Corewell Health
- Start
- Dec 2016
- Primary completion
- Jun 2023
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing Vancomycin with Placebo (2 arms). Primary endpoint: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile at 12 weeks. Started Dec 2016; status: completed.
02
Drugs
vancomycin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02996487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996487.